Table 2. Rosuvastatin Evoked Protection against CFA-Prompted Arthritis.
| Paw
volume changes (mL) |
|||||
|---|---|---|---|---|---|
| experimental groups | 0 day | 7th day | 14th day | 21st day | 28th day |
| disease control (3 mL/kg distilled water) | 1.22 ± 0.146 | 2.60 ± 0.046 | 3.21 ± 0.061 | 3.04 ± 0.034 | 2.95 ± 0.075 |
| standard drug Piroxicam (10 mg/kg) | 0.95 ± 0.055ns | 1.52 ± 0.131*** (41.53%) | 1.50 ± 0.063*** (53.27%) | 1.11 ± 0.078*** (63.48%) | 0.88 ± 0.112*** (70.16%) |
| Rosuvastatin (40 mg/kg) | 0.95 ± 0.070ns | 1.55 ± 0.105*** (40.38%) | 1.54 ± 0.067*** (52.02%) | 1.21 ± 0.042*** (60.19%) | 0.96 ± 0.045*** (67.45%) |
a
Data are represented as mean ± SEM, where n = 6, and analyzed by two-way ANOVA followed by the Bonferroni post-test, where ***p < 0.001, **p < 0.01, *p < 0.05, ns = not significant. The values in parentheses represent percentage inhibition of paw edema compared to the control group calculated according to the above-mentioned formula.